NIH announces intent to reissue a Funding Opportunity Announcement for the Rare Disease Clinical Research Network competition.
Increased skin cancer risks in DM1 are captured in a new, longitudinal electronic medical records study.
A recent publication suggests that a serum protein may ultimately have value as a biomarker for conduction system abnormalities in DM.
CRISPR is an exploratory strategy with potential for treatment of RNA-triggered diseases. Will DNA or RNA targeting prove to be the best approach for DM?
Genetic and epigenetic mechanisms drive differences between CDM and DM1—a new study elucidates downstream signaling pathways that underlie their diverse phenotypes and represent putative therapy development targets for CDM.